Furthermore, pathways related to cell cycle progression (G2M checkpoint and E2F targets) were enriched in TET2-deficient AML, indicating increased growth upon loss of TET2, consistent with the effects observed in the cell model (Supplemental Fig. 2d; Supplemental Fig. 2j). The gene discussed is TET2; the disease is acute myeloid leukemia.